Clearside IPO – $50 Million

Washington, DC – June 21, 2016 – Cooley advised Clearside Biomedical on its $50.4 million initial public offering. The company's common stock trades on the NASDAQ Global Market under the symbol "CLSD."

Cowen and Company and Stifel, Nicolaus & Company acted as joint book-running managers for the offering, and Needham & Company and Wedbush Securities acted as co-managers.

Clearside is a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. In addition to representing Clearside in the offering, Cooley has served as intellectual property counsel to the company since 2012.

The Cooley corporate and securities team included Brent Siler, Darren DeStefano, Brian Leaf, Katie Kazem, Mark Ballantyne and Jennifer Don.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

Related Contacts
Brent Siler Partner, Washington, DC
Darren DeStefano Partner, Reston
Brian Leaf Partner, Reston
Katie Kazem Associate, Reston
Mark Ballantyne Associate, Reston
Jennifer Don Senior Paralegal, Reston
Michael Tuscan Partner in Charge - Washington, DC
Erik Milch Partner, Reston
Jeremy Binstock Associate, Reston
Natasha Leskovsek Partner, Washington, DC
Phil Mitchell Partner, New York
Susan Cooper Philpot Retired Partner, San Francisco
Mark Windfeld-Hansen Partner, Palo Alto
Francis Wheeler Partner, Colorado